NDLI: New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells

Content Provider	PubMed Central
Author	Gottfried, Eva Lang, Sven A. Renner, Kathrin Bosserhoff, Anja Gronwald, Wolfram Michael, Rehli Sabine, Einhell Isabel, Gedig Singer, Katrin Anton, Seilbeck Mackensen, Andreas Grauer, Oliver Hau, Peter Dettmer, Katja Andreesen, Reinhard Oefner, Peter J. Kreutz, Marina
Editor	Rafael, Moreno-sanchez
Copyright Year	2013
Abstract	Non-steroidal anti-inflammatory drugs such as diclofenac exhibit potent anticancer effects. Up to now these effects were mainly attributed to its classical role as COX-inhibitor. Here we show novel COX-independent effects of diclofenac. Diclofenac significantly diminished MYC expression and modulated glucose metabolism resulting in impaired melanoma, leukemia, and carcinoma cell line proliferation in vitro and reduced melanoma growth in vivo. In contrast, the non-selective COX inhibitor aspirin and the COX-2 specific inhibitor NS-398 had no effect on MYC expression and glucose metabolism. Diclofenac significantly decreased glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and monocarboxylate transporter 1 (MCT1) gene expression in line with a decrease in glucose uptake and lactate secretion. A significant intracellular accumulation of lactate by diclofenac preceded the observed effect on gene expression, suggesting a direct inhibitory effect of diclofenac on lactate efflux. While intracellular lactate accumulation impairs cellular proliferation and gene expression, it does not inhibit MYC expression as evidenced by the lack of MYC regulation by the MCT inhibitor α-cyano-4-hydroxycinnamic acid. Finally, in a cell line with a tetracycline-regulated c-MYC gene, diclofenac decreased proliferation both in the presence and absence of c-MYC. Thus, diclofenac targets tumor cell proliferation via two mechanisms, that is inhibition of MYC and lactate transport. Based on these results, diclofenac holds potential as a clinically applicable MYC and glycolysis inhibitor supporting established tumor therapies.
Related Links	http://dx.doi.org/10.1371/journal.pone.0066987
Starting Page	66987
File Format	PDF
ISSN	19326203
e-ISSN	19326203
Journal	PLoS ONE
Issue Number	7
Volume Number	8
Language	English
Publisher	Public Library of Science
Publisher Date	2013-07-01
Access Restriction	Open
Rights Holder	Public Library of Science
Subject Keyword	Biochemistry, Genetics and Molecular Biology(all) Agricultural and Biological Sciences(all) Medicine(all) Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Multidisciplinary

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The Tumor-Suppressive MicroRNA-135b Targets c-Myc in Osteoscarcoma

New Targets for Drug Discovery against Malaria

BSA Nanoparticle Loaded Atorvastatin Calcium - A New Facet for an Old Drug

Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells

Subarachnoid Space: New Tricks by an Old Dog

Yersinia pestis: New Evidence for an Old Infection

Targeting c-MYC with T-Cells

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc

New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells

Similar Documents

The Tumor-Suppressive MicroRNA-135b Targets c-Myc in Osteoscarcoma

New Targets for Drug Discovery against Malaria

BSA Nanoparticle Loaded Atorvastatin Calcium - A New Facet for an Old Drug

Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells

Subarachnoid Space: New Tricks by an Old Dog

Yersinia pestis: New Evidence for an Old Infection

Targeting c-MYC with T-Cells

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc

New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells